Cargando…
Botulinum toxin type A promotes microglial M2 polarization and suppresses chronic constriction injury-induced neuropathic pain through the P2X7 receptor
BACKGROUND: Switching microglial polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype represents a novel therapeutic strategy for neuropathic pain (NP). This study aims to investigate whether botulinum toxin type A (BTX-A) regulates microglial M1/M2 polarization...
Autores principales: | Gui, Xianwei, Wang, Hansen, Wu, Lanxiang, Tian, Sheng, Wang, Xuan, Zheng, Heqing, Wu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092425/ https://www.ncbi.nlm.nih.gov/pubmed/32211150 http://dx.doi.org/10.1186/s13578-020-00405-3 |
Ejemplares similares
-
Botulinum toxin type A alleviates neuropathic pain and suppresses inflammatory cytokines release from microglia by targeting TLR2/MyD88 and SNAP23
por: Wang, Xuan, et al.
Publicado: (2020) -
The role of botulinum toxin type A related axon transport in neuropathic pain induced by chronic constriction injury
por: Bu, Huilian, et al.
Publicado: (2022) -
Botulinum Toxin for Central Neuropathic Pain
por: Park, Jihye, et al.
Publicado: (2018) -
Botulinum Toxin for the Treatment of Neuropathic Pain
por: Park, JungHyun, et al.
Publicado: (2017) -
Effect of botulinum toxin type A on non-motor symptoms and quality of life in Meige syndrome
por: Zheng, Heqing, et al.
Publicado: (2023)